A series of three complexes with diethyldithiocarbamate ligand and three different metals (Ni, Cu, Zn) was prepared, confirmed by X-ray crystallography, and tested in human breast cancer MDA-MB-231 cells. Zinc and copper complexes, but not nickel complex, were found to be more active against cellular 26S proteasome than against purified 20S proteasome core particle. One of the possible explanations is inhibition of JAMM domain in the 19S proteasome lid.

Department of Medical Chemistry and Biochemistry Department of Cell Biology and Genetics Palacky University Olomouc 77515 Czech Republic

Zobrazit více v PubMed

Rang HP, Dale MM, Ritter JM, Gardner P. Pharmacology. Churchill Livingstone; New York: 2001.

Huang R, Wallqvist A, Covell DG. Anticancer metal compounds in NCI’s tumor-screening database: putative mode of action. Biochem. Pharmacol. 2005;69:1009–1039. PubMed

Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2007;448:645–646. PubMed

Cvek B, Dvorak Z. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discovery Today. 2008;13:716–722. PubMed

Chen D, Dou QP. New uses for old copper-binding drugs: converting the proangiogenic copper to a specific cancer cell death inducer. Expert Opin. Ther. Targets. 2008;12:739–748. PubMed PMC

Brar SS, Grigg C, Wilson KS, Holder WD, Dreau D, Austin C, Foster M, Ghio AJ, Whorton AR, Stowell GW, Whittall LB, Wittle RR, White DP, Kennedy TP. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in patient with metastatic disease. Mol. Cancer Ther. 2004;3:1049–1060. PubMed

Cen D, Brayton D, Shahandeh B, Meyskens FL, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J. Med. Chem. 2004;47:6914–6920. PubMed

Johansson B. A review of the pharmacokinetics and pharmacody-namics of disulfiram and its metabolites. Acta Psychiatr. Scand., Suppl. 1992;369:15–26. PubMed

Giovagnini L, Ronconi L, Aldinucci D, Lorenzon D, Sitran S, Fregona D. Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes. J. Med. Chem. 2005;48:1588–1595. PubMed

Milacic V, Chen D, Ronconi L, Landis-Piwowar KR, Fregona D, Dou QP. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res. 2006;66:10478–10486. PubMed

Viola-Rhenals M, Rieber MS, Rieber M. Role of peroxidases, thiols and Bak/Bax in tumor cell susceptibility to Cu[DEDTC]2. Biochem. Pharmacol. 2007;74:841–850. PubMed

Saggioro D, Rigobello MP, Paloschi L, Folda A, Moggach SA, Parsons S, Ronconi L, Fregona D, Bindoli A. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol. 2007;14:1128–1139. PubMed

Chen D, Cui QZC, Yang HJ, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66:10425–10433. PubMed

Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008;14:1649–1657. PubMed

Borissenko L, Groll M. 20 S proteasome and its inhibitors: crystal-lographic knowledge for drug development. Chem. Rev. 2007;107:687–717. PubMed

Husnjak K, Elsasser S, Zhang NX, Chen X, Randles L, Shi Y, Hofmann K, Walters KJ, Finley D, Dikic I. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature. 2008;453:481–488. PubMed PMC

Verma R, Aravind L, Oania R, McDonald WH, Yates JR, Koonin EV, Deshaies RJ. Role of Rpn11 metallprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002;298:611–615. PubMed

Ambroggio XI, Rees DC, Deshaies RJ. JAMM: a metallopro-tease-like zinc site in the proteasome and signalosome. PLoS Biol. 2004;2:113–119. PubMed PMC

Gallery M, Blank JL, Lin Y, Gutierrez JA, Pulido JC, Rappoli D, Badola S, Rolfe M, MacBeth KJ. The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol. Cancer Ther. 2007;6:262–268. PubMed

Hogarth G. Transition metal dithiocarbamates: 1978-2003. Prog. Inorg. Chem. 2005;53:71–561.

Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit. Nat. Rev. Cancer. 2007;7:659–672. PubMed

Daniel KG, Gupta P, Harbach RH, Guida WC, Dou QP. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem. Pharmacol. 2004;67:1139–1151. PubMed

Chen D, Frezza M, Shakya R, Cui QC, Milacic V, Verani CN, Dou QP. Inhibition of the proteasome activity by gallium(III) complexes contributes to their antiprostate tumor effects. Cancer Res. 2007;67:9258–9265. PubMed

Suzuki Y, Fujii S, Tominaga T, Yoshimoto T, Yoshimura T, Kamada H. The origin of an EPR signal observed in dithiocarbamate-loaded tissues. Copper(II)-dithiocarbamate complexes account for the narrow hyperfine lines. Biochim. Biophys. Acta. 1997;1335:242–245. PubMed

Cope GA, Suh GSB, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, Deshaies RJ. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science. 2002;289:608–611. PubMed

Cvek B, Dvorak Z. Targeting of nuclear factor-κB and proteasome by dithiocarbamate complexes with metals. Curr. Pharm. Des. 2007;13:3155–3167. PubMed

Larsen KS, Auld DS. Characterization of an inhibitory metal binding site in carboxypeptidase A. Biochemistry. 1991;30:2613–2618. PubMed

Georgieva I, Trendafilova N. Bonding analyses, formation energies, and vibrational properties of M-R2dtc complexes (M) Ag(I), Ni(II), Cu(II), or Zn(II)) J. Phys. Chem. A. 2007;111:13075–13087. PubMed

Milacic V, Chen D, Giovagnini L, Diez A, Fregona D, Dou QP. Pyrrolidine dithiocarbamate-zinc(II) and-copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol. Appl. Pharmacol. 2008;231:24–33. PubMed PMC

Chen J, Du CS, Kang JH, Wang JM. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis. Chem. Biol. Interact. 2008;171:26–36. PubMed

Yamada T, Mizuno K, Hirota K, Kon N, Wahls WP, Hartsuiker E, Murofushi H, Shibata K, Ohta K. Roles of histone acetylation and chromatin remodeling factor in a meiotic recombination hotspot. EMBO J. 2004;23:1792–1803. PubMed PMC

Zhu P, Zhou WL, Wang JX, Puc J, Ohgi KA, Erdjument-Bromage H, Tempst P, Glass CK, Rosenfeld MG. A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol. Cell. 2007;27:609–621. PubMed PMC

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4

Deubiquitinases (DUBs) and DUB inhibitors: a patent review